Tempest Therapeutics

The latest publications for Tempest Therapeutics, a clinical-stage biotechnology company that develops small molecule therapeutics designed to effectively treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Tempest Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to effectively treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Tempest Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to treat cancer by directly killing tumor cells and activating tumor-specific immunity.

Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.

Tempest Therapeutics secures a $7.5 million private placement, including a $2.5 million upfront payment and up to $5 million in potential proceeds from warrant exercises. The funding supports the biotech company’s growth and operational expansion.

Sep 2026GlobeNewswireNews article

Tempest partners with Senlang Biotechnology to advance **TPST-4003**, a next-generation in vivo CAR-T therapy targeting **CD7**. The candidate integrates Tempest’s proprietary **CD7-targeted mRNA/LNP delivery** with a dual-target **CD19/BCMA CAR** design. This collaboration aims to leverage Senlang’s expertise in biotechnology to develop an innovative approach for treating hematologic malignancies.

Jul 2026GlobeNewswireNews article

Tempest introduces a next-generation in vivo CAR-T pipeline targeting oncology and immunology. The approach uses CD7-targeted mRNA/LNP delivery to differentiate its product candidates. The company plans to initiate its first clinical study in the fourth quarter of 2026.

Jul 2026GlobeNewswireNews article

Tempest Therapeutics adds Drake Richey and John Yee, MD, MPH, to its board of directors. Both bring expertise in biopharmaceuticals and leadership experience. Richey previously held executive roles at a biotech company, while Yee has a background in public health and medical research. The appointments aim to strengthen Tempest’s strategic and scientific advisory capabilities.

Jun 2026GlobeNewswireNews article